Chemistry:MSP-2020

From HandWiki

MSP-2020 is a psychedelic drug of the tryptamine and pyrrolidinylmethylindole families related to psilocybin which is under development for the treatment of mental disorders such as major depressive disorder.[1][2][3][4][5][6][7] It is taken orally.[1] The drug acts as a serotonin 5-HT2A receptor agonist and is described as a prodrug.[1][3][8] It is a 3-pyrrolidine–indole derivative and hence cyclized tryptamine and is said to be psilocybin-like but with stronger effects and a shorter duration.[1][5][6][7] MSP-2020 was originated by Mindset Pharma and is now under development by Otsuka America Pharmaceutical, which acquired Mindset Pharma in January 2024.[1][2][3][4] As of January 2026, MSP-2020 is in phase 1 clinical trials for major depressive disorder.[1][2][3] MSP-2020 was patented by Mindset Pharma in 2021, though its specific chemical structure has not been disclosed and is unclear.[1][7][5][6]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "MSP 2020". 14 January 2026. https://adisinsight.springer.com/drugs/800070476. "MSP 2020 is an oral pyrrolidine-indole derivative psilocybin like high potency, short acting drug being developed by Otsuka America [...]" 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on MSP-2020 with Synapse". 12 January 2026. https://synapse.patsnap.com/drug/37179bf1df5742e4ace1bde7768dd4ca. 
  3. ↑ 3.0 3.1 3.2 3.3 "MSP-2020 Drug Profile". https://pryzm.ozmosi.com/product/27415. 
  4. ↑ 4.0 4.1 "Otsuka makes psychedelics play, buying Mindset". September 2023. https://pharmaphorum.com/news/otsuka-makes-psychedelics-play-buying-mindset. "To date, Otsuka has been working with Mindset on the company's second family of psilocybin-based drug candidates led by MSP-2020 and back-up compound MSP-2003, which offer "greater potency than LSD combined with a shorter psychedelic effect than psilocybin."" 
  5. ↑ 5.0 5.1 5.2 "Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder". ACS Medicinal Chemistry Letters 16 (1): 18–19. January 2025. doi:10.1021/acsmedchemlett.4c00581. PMID 39811142. 
  6. ↑ 6.0 6.1 6.2 "3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders". 4 February 2021. https://patents.google.com/patent/WO2021155467A1/en. 
  7. ↑ 7.0 7.1 7.2 Pharma M (5 October 2022). "Mindset Pharma Selects Lead Clinical Candidates From "Family 2" of its Next Generation Psychedelic Drug Portfolio". GlobeNewswire News Room (Press release). Retrieved 15 January 2026. MSP-2020 and MSP-2003, exhibiting a stronger and shorter acting psychedelic effect than psilocybin in preclinical testing, are selected for IND enabling studies [...] ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that after extensive preclinical screening studies, a lead psychedelic drug clinical candidate, MSP-2020, and a second back-up drug candidate, MSP-2003, have been selected from its Family 2 program in collaboration with The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, to advance to IND enabling studies. [...] MSP-2020 and MSP-2003 are both novel and patentable compounds. They are covered under Mindset's United States Patent and Trademark Office (USPTO) patent number 17/387,864, titled "3-Pyrrolidine-Indole Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders." Mindset has received a notice of allowance from the USPTO for this application. [...] In side-by-side comparisons to psilocybin and psilocin, the two drug candidates elicit in vitro and behavioral responses consistent with a stronger and shorter acting psychedelic effect than psilocybin and a significantly reduced half-life. The drug candidates are CNS penetrant and exhibit high oral bioavailability in different species.
  8. ↑ "Mindset Pharma Inc. Scientific Summary February 2021". February 2021. https://uploads-ssl.webflow.com/5fbd8bccac01444848c8dc50/604f4ab8b2f5560f4acfd87b_Mindset%20Scientific%20Presentation%20-%20March%2016.pdf. "In Vitro Profile of Selected Mindset Prodrug Candidates" 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:MSP-2020&oldid=4357669"